Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Report

Human Immunodeficiency Virus Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease), And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-210-5
  • Number of Pages: 75
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2015
  • Industry: Healthcare

Table of Content

Chapter 1 Methodology & Scope
                   1.1 Research Methodology
                   1.2 Research Scope & Assumptions
                   1.3 List of Data Sources
Chapter 2 Executive Summary and Market Snapshot
                   2.1 Market Snapshot
Chapter 3 HIV-1 Therapeutics Market Variables, Trends& Scope
                   3.1 Market segmentation & scope
                   3.2 Market size and growth prospects
                      3.2.1 Market Driver Analysis
                      3.2.2 Market Restraint Analysis
                   3. Penetration & growth prospect mapping
                   3.4 HIV-1 Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
                   3.5 Industry Analysis - Porter’s
Chapter 4 HIV-1 TherapeuticsMarket Drug Class Estimates & Trend Analysis
                   4.1 HIV-1 Therapeutics market: Drug Class movement analysis
                   4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
                      4.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
                      4.3.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.4 Entry and Fusion Inhibitors
                      4.4.1 Entry and fusion Inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.5 Protease Inhibitors (PIs)
                      4.5.1 Protease Inhibitors (PIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.6 Integrase Inhibitors
                      4.6.1 Integrase inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.7 Coreceptor Antagonists
                      4.7.1 Coreceptor antagonists market estimates and forecasts, by drug class, 2014 - 2025 USD Million
Chapter 5 HIV-1 Therapeutics Market Regional Estimates & Trend Analysis
                   5.1 HIV-1 Therapeutics market share by region, 2014& 2025
                   5.2 North America
                      5.2.1 North America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.2.1.1 U.S.
                            5.2.1.2 Canada
                   5.3 Europe
                      5.3.1 Europe market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.3.1.1 UK
                            5.3.1.2 Germany
                   5.4 Asia Pacific
                      5.4.1 Asia Pacific market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.4.1.1 Japan
                            5.4.1.2 China
                            5.4.1.3 India
                   5.5 Latin America
                      5.5.1 Latin America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.5.1.1 Mexico
                            5.5.1.2 Brazil
                   5.6 MEA
                      5.6.1 MEA market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.6.1.1 South Africa
Chapter 6 Competitive Landscape
                   6.1 Strategy framework
                   6.2 Company Profiles
                      6.2.1 AbbVie, Inc.
                            6.2.1.1 Company Overview
                            6.2.1.2 Financial Performance
                            6.2.1.3 Product Benchmarking
                            6.2.1.4 Strategic Initiatives
                      6.2.2 Boehringer Ingelheim GmbH
                            6.2.2.1 Company Overview
                            6.2.2.2 Financial Performance
                            6.2.2.3 Product Benchmarking
                            6.2.2.4 Strategic Initiatives
                      6.2.3 Bristol-Myers Squibb Company
                            6.2.3.1 Company Overview
                            6.2.3.2 Financial Performance
                            6.2.3.3 Product Benchmarking
                            6.2.3.4 Strategic Initiatives
                      6.2.4 Cipla, Inc.
                            6.2.4.1 Company Overview
                            6.2.4.2 Financial Performance
                            6.2.4.3 Product Benchmarking
                            6.2.4.4 Strategic Initiatives
                      6.2.5 Genentech, Inc.
                            6.2.5.1 Company Overview
                            6.2.5.2 Financial Performance
                            6.2.5.3 Product Benchmarking
                            6.2.5.4 Strategic Initiatives
                      6.2.6 Gilead Sciences, Inc.
                            6.2.6.1 Company Overview
                            6.2.6.2 Financial Performance
                            6.2.6.3 Product Benchmarking
                            6.2.6.4 Strategic Initiatives
                      6.2.7 Merck & Co., Inc.
                            6.2.7.1 Company Overview
                            6.2.7.2 Financial Performance
                            6.2.7.3 Product Benchmarking
                            6.2.7.4 Strategic Initiatives
                      6.2.8 ViiV Healthcare
                            6.2.8.1 Company Overview
                            6.2.8.2 Financial Performance
                            6.2.8.3 Product Benchmarking
                            6.2.8.4 Strategic Initiatives


List of Tables

TABLE 1 Country share estimation
TABLE 2 North America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 3 U.S. HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 4 Canada HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 5 Europe HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 6 UK HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 7 Germany HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 8 Asia Pacific HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 9 Japan HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 10 China HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 11 India HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 12 Latin America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 13 Mexico HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 14 Brazil HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 15 MEA HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 16 South Africa HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)


List of Figures

FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 HIV-1 Therapeutics: Market Segmentation
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 HIV-1 TherapeuticsPorter’s analysis
FIG. 9 HIV-1 Therapeutics market Drug Classes outlook key takeaways
FIG. 10 HIV-1 Therapeutics market: Drug Classes movement analysis
FIG. 11 Globa lNRTIs market, 2014 - 2025 (USD Million)
FIG. 12 Global NNRTIs market, 2014 - 2025 (USD Million)
FIG. 13 Global Entry and Fusion Inhibitors market, 2014 - 2025 (USD Million)
FIG. 14 Global Protease Inhibitors (PIs) market, 2014 - 2025 (USD Million)
FIG. 15 Global Integrase Inhibitors market, 2014 - 2025 (USD Million)
FIG. 16 Global Coreceptor Antagonists market, 2014 - 2025 (USD Million)
FIG. 17 Regional market place: Key takeaways
FIG. 18 Regional outlook, 2015 & 2026
FIG. 19 Strategy framework
FIG. 20 Participant categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon